沙特阿拉伯唾液腺疾病及其相关因素的现状理解
Current understanding of salivary gland disorders and related factors in Saudi Arabia: epidemiology, risk factors, clinical features, and future perspectives
这篇综述总结了沙特阿拉伯唾液腺疾病的现状及其相关因素,主要基于回顾性和横断面研究。研究发现,尽管提供了有关疾病流行病学、临床特征和风险因素的有价值见解,但缺乏全国范围内的流行病学数据,且对糖尿病、吸烟、肥胖等其他影响因素的研究有限。未来研究应侧重于大规模多中心流行病学研究,以改善疾病监测、促进早期诊断并支持基于证据的预防和管理策略。
Abstract
Salivary gland (SG) disorders comprise a diverse group of conditions that impair SG structure and function, leading to SG hypofunction, hyposalivation, xerostomia, and reduced quality of life. This narrative review summarizes current understanding of common SG disorders and the factors associated with SG dysfunction, with particular emphasis on evidence from Saudi Arabia. Relevant Saudi studies were identified through a comprehensive literature search to provide an overview of the available evidence. The Saudi literature is predominantly composed of retrospective and cross-sectional studies, case series, and case reports, with limited research on molecular mechanisms and salivary function. It is also characterized by considerable methodological heterogeneity and a paucity of nationwide epidemiological data. These studies offer valuable insights into the epidemiology, clinical characteristics, diagnosis, treatment, and risk factors of SG disorders. However, they remain insufficient to determine the true national burden and distribution of these conditions. In addition, the available Saudi evidence is largely focused on SG tumors and Sjögren’s syndrome, whereas data on other factors associated with SG dysfunction, including diabetes mellitus, smoking, obesity, aging, xerogenic medications, and head and neck radiotherapy, are limited or absent. Future research should prioritize large-scale, multicenter epidemiological studies, the establishment of national disease registries, standardized diagnostic criteria, and longitudinal investigations to improve disease surveillance, facilitate early diagnosis, and support evidence-based prevention and management strategies in Saudi Arabia. This review provides a foundation for addressing current knowledge gaps and guiding future research, policy development, and clinical practice in Saudi Arabia.
Overview of salivary glands
Salivary glands (SGs) are exocrine glands in the head and neck that produce and secrete saliva. They are classified as major and minor glands based on size and salivary output1. The three major glands are the parotid gland (PG), the submandibular gland (SMG), and the sublingual gland (SL), in addition to hundreds of minor glands2.
Approximately 1.5 L of saliva is secreted into the oral cavity daily, with more than 90% produced by the major SGs and the remainder by the minor SGs3,4. In most healthy adults, unstimulated salivary flow is about 0.5 mL/min, whereas stimulated salivary flow ranges from 1 to 3 mL/min (e.g., in response to smell, taste, and chewing of food)4,5,6.
Saliva comprises 99% water and about 1% of proteins, electrolytes, and ions7,8. These components play essential roles in the oral cavity, as summarized in Supplementary Table S14,6,9. This narrative review provides an overview of the current understanding of salivary gland (SG) disorders and the factors that contribute to SG dysfunction in Saudi Arabia.
Methods
A literature search was conducted in PubMed/MEDLINE and Google Scholar to identify studies on SG disorders in Saudi Arabia. Studies published between 2017 and 2026 were included. The search strategy combined terms related to SG disorders, epidemiology, risk factors, xerostomia, hyposalivation, autoimmune diseases, head and neck cancer, diabetes mellitus, smoking, obesity, hypertension, cardiovascular diseases, depressive disorders, and Saudi Arabia. Original research articles, case series, case reports, questionnaire-based studies, salivary function studies, and molecular studies published in English were included. Studies involving the Saudi population were prioritized, although relevant international studies were included to provide context. Conference abstracts and studies lacking sufficient methodological detail were excluded. Articles were selected based on their relevance to the epidemiology, risk factors, and clinical presentation of SG disorders. The literature search, study selection, and data extraction were conducted by the author. A total of 24 studies from Saudi Arabia were included in this review, and the literature search was last updated on September 16, 2026. As this was a narrative review, no formal risk-of-bias assessment was performed. Instead, the included studies were evaluated based on their study design, sample size, study setting, and methodological limitations, where appropriate. The retrieved literature was synthesized by topic. Figures and tables were developed by compiling, extracting, and visually summarizing data from the included studies. Numerical data were extracted to generate graphical summaries; only descriptive calculations were performed, and no new statistical analyses or original datasets were generated.
Factors involved in SG dysfunction
Various factors, including SG disorders and other systemic or predisposing factors, can impair SG function, leading to SG hypofunction and, in severe cases, irreversible SG damage10. SG hypofunction is defined as a reduction in secretory function and is characterized by decreased salivary flow (hyposalivation)11 and altered saliva composition7. In contrast, xerostomia is the subjective sensation of oral dryness and can occur with or without SG hypofunction12,13.
SG disorders encompass sialadenitis14, sialolithiasis15, Sjögren’s syndrome16, and SG tumors17. Other factors associated with SG hypofunction, or xerostomia, or both include diabetes mellitus18, autoimmune disorders16, xerogenic medications19, aging20, radiotherapy for head and neck cancer21, human immunodeficiency virus (HIV) infection, smoking, obesity, alcohol consumption, and dehydration (Fig. 1)22,23,24,25.
Schematic illustration of the major factors associated with SG hypofunction, with or without xerostomia. Dehydration may contribute to the development of sialolithiasis. Reduced salivary secretion due to SG hypofunction can contribute to sialolithiasis. Conversely, sialolithiasis can cause ductal obstruction, leading to SG hypofunction and potentially contributing to sialadenitis (dark red line). Sialadenitis can arise from bacterial or viral infections and may also occur secondary to systemic conditions. SG hypofunction can also contribute to sialadenitis (green line). Primary Sjögren’s syndrome causes structural damage to the SGs, leading to SG hypofunction and xerostomia, whereas Sjögren’s syndrome may occur in association with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (yellow line). Radiotherapy for head and neck cancer, including SG cancer, can result in SG hypofunction and xerostomia through radiation-induced structural and histological damage to the SGs (red line). Aging can contribute to structural changes in the SGs; however, its effects are often influenced by multimorbidity and polypharmacy (purple line). HIV infection (gray line) and xerogenic medications (brown line) are also associated with SG hypofunction, with or without xerostomia. Lifestyle factors, including smoking, obesity, and alcohol consumption, may lead to SG hypofunction, with or without xerostomia (orange line). In diabetes mellitus, dehydration and other disease-related mechanisms can contribute to hyposalivation, with or without xerostomia (blue line). The schematic illustration was created using BioRender.com.
In addition, SG dysfunction can affect quality of life by increasing the risk of oral infections and causing difficulties with swallowing, speech, and digestion26,27. No cure exists to restore impaired SG function, and available treatments provide only temporary symptomatic relief28,29.
SG disorders
Sialadenitis, sialolithiasis, Sjögren’s syndrome, and SG tumors are the most commonly reported SG disorders; however, their prevalence varies by gland type (Fig. 2). The following sections provide an overview of these disorders, integrating current evidence on their epidemiology, pathogenesis, and clinical features, with a particular focus on studies conducted in Saudi Arabia.
Anatomical distribution of major SG disorders. Sialadenitis most commonly affects the PG; however, its incidence has not been reported. It affects the SMG in approximately 10% of cases and is rarely observed in the SL, where no reliable estimate is available. Sialolithiasis primarily affects the SMG, followed by the PG (19%) and the SL (1%). Salivary gland tumors most frequently involve the PG (70%), followed by the SMG (10%), whereas the SL is the least common site (<1%). Approximately 20% of salivary gland tumors arise in the minor SGs (not shown). The figure was created using BioRender.com.
Sialadenitis
Sialadenitis is inflammation of the SGs caused by infections, obstructions, or autoimmune conditions14. Although any of the major SGs can develop sialadenitis, approximately 10% of cases involve the SMG30, whereas the PG is the most commonly affected gland; sialadenitis of the PG is referred to as parotitis (Fig. 2)22. However, reliable estimates of the incidence of parotitis and sialadenitis involving the SL are unavailable. Parotitis is classified as acute or chronic and may result from various etiologies, including bacterial and viral infections, autoimmune diseases, or metabolic disorders31. Acute parotitis had a mortality rate of approximately 50% before the modern antibiotic era, making it a serious postoperative complication32. Following the introduction of antimicrobial therapy, the incidence has declined to 0.02%–0.04% of hospital admissions33. Juvenile recurrent parotitis (JRP) is a recurrent form of parotitis that primarily affects children aged 3–6 and 9–11 years34, whereas chronic parotitis most commonly affects patients aged 40–60 years35. However, a recent study reported a mean age of 27.2 years in Saudi Arabia among the overall study population, including both children and adults36. In addition, parotitis appears to be more common in males than in females during childhood and is equally distributed among adults37,38. In a Saudi study, males were more frequently affected when children and adults were combined36. The incidence of parotitis among children and adults during the antibiotic era remains unclear in the literature. For example, a systematic review of 27 studies reported 524 pediatric cases of parotitis34, whereas a single study reported 1,008 cases39.
Our recent findings identified 1,340 cases of parotitis over a 9-year period (2015–2023) within a multicenter hospital-based study across three regions (Central, Eastern, and Western) of Saudi Arabia. In this study, a higher frequency of cases was observed in children than in adults36. Another study reported five cases of chronic parotitis among 183 patients who underwent parotidectomy over 12 years (2006–2018) at two tertiary centers in the capital of Saudi Arabia40. The remaining studies conducted in Saudi Arabia were primarily case reports of parotitis associated with various underlying conditions. For example, one study reported three cases of chronic parotitis in female patients aged 47, 77, and 82 years, all diagnosed with Sjögren’s syndrome. These patients did not respond to intravenous antibiotics but were successfully managed with conservative treatment41. Another study described a case of JRP in an 8-year-old Saudi child who experienced multiple attacks over a 2-year period42. In addition, recurrent parotitis has been documented in a 15-year-old Saudi female with lipoid proteinosis, a rare autosomal recessive disorder. The patient presented with multiple missing teeth and poor oral hygiene (Supplementary Table S2)43. This underscores that the epidemiology of parotitis varies across populations and is influenced by several etiological factors, including vaccination coverage, age-related physiological changes, autoimmune diseases, sialolithiasis, metabolic disorders, dehydration, and reduced salivary flow38,44. The relatively high number of parotitis cases reported in the aforementioned multicenter hospital-based study suggests that parotitis is an important clinical condition in Saudi Arabia. However, as the study was hospital-based, these findings should not be interpreted as representative of the national burden of disease. Despite the limited number of case reports and case series, the available evidence highlights the diverse etiological spectrum of parotitis in Saudi Arabia, including infectious, autoimmune, and rare genetic causes.
Sialolithiasis
Sialolithiasis is a common disorder of the major SGs characterized by the formation of salivary stones (sialoliths). It affects approximately 1 in 15,000 to 1 in 30,000 individuals aged 40–50 years45,46. According to recent findings from a Saudi cohort, the mean age of patients with sialolithiasis was 39.8 years47. Before 1990, sialolithiasis predominantly affected males; however, more recent studies have reported either an equal gender distribution or a higher incidence among females48,49,50. These stones are most frequently observed in the SMG, followed by the PG, and are rarely found in the SL or minor glands (Fig. 2)51,52. Sialoliths are calcified structures located within the salivary ducts or within the gland parenchyma, resulting in obstruction of salivary flow, which causes pain and swelling, particularly during mealtimes15,46.
Although the mechanism underlying sialolithiasis remains unclear, reduced salivary flow due to tobacco smoking, certain medications53, and elevated body mass index (BMI)54 have been proposed as risk factors. Over a 9-year period, a retrospective study at a multicenter hospital across the Central, Western, and Eastern regions of Saudi Arabia recorded 375 Saudi patients with sialolithiasis and various systemic diseases. The findings suggested that salivary stone formation may be influenced by comorbidities such as diabetes mellitus, dyslipidemia, and hypertension47. Obstruction of salivary flow by salivary stones can lead to chronic sialadenitis38. Based on two retrospective studies conducted at the National Guard Health Affairs in Saudi Arabia between 2016 and 2023, sialolithiasis was less prevalent than parotitis (Fig. 3)36,47.
Descriptive comparison of the annual published case counts for parotitis and sialolithiasis from two multicenter retrospective studies conducted in Saudi Arabia. Both studies were conducted within the Ministry of National Guard Health Affairs (NGHA) healthcare system using the BestCare electronic health record database. Although the studies had comparable healthcare settings and geographic coverage, they differed in their observation periods. Therefore, this figure provides a descriptive comparison of the published annual case counts rather than a direct comparison of disease frequency36,47.
Interestingly, one study documented a case of an 85-year-old Saudi patient with a giant SMG stone who declined treatment. Review of an orthopantomogram obtained 12 years earlier revealed the same stone at a smaller size, suggesting progressive enlargement over time55. Another Saudi case series reported four patients with submandibular duct sialolithiasis. Three patients were successfully treated by transoral sialolith removal using forceps, whereas one patient experienced spontaneous self-exfoliation of the stone before the planned procedure. The authors noted that most patients with suspected sialoliths seek medical care when the condition presents acutely (Table S2)56. However, these observations may be influenced by referral bias, diagnostic availability, regional differences, and access to healthcare. Diagnosis of sialolithiasis should begin with a thorough history and physical examination, followed by imaging based on the clinical presentation and suspected stone location. Ultrasonography is typically the initial imaging modality, whereas computed tomography is reserved for selected cases. Sialography is useful for detecting radiolucent stones but is contraindicated during acute sialadenitis. Sialendoscopy serves both diagnostic and therapeutic purposes15.
Sjögren’s syndrome
Sjögren’s syndrome (SS) is a common systemic autoimmune disease that primarily affects the SGs and lacrimal glands. It can occur in the absence of another autoimmune disease (primary SS) or in association with other autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)16. SS predominantly affects middle-aged women, with a female-to-male ratio of 9:157. A similar female predominance was observed in a Saudi cohort. The study further classified patients into early-onset (< 40 years) and late-onset (≥ 40 years) primary SS, with mean ages of approximately 34 and 60 years, respectively58.
According to the 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for SS, diagnosis is based on five items: labial SG biopsy, anti-Ro/SSA positivity, ocular staining score, Schirmer’s test, and unstimulated whole saliva flow rate16. More than 80% of patients with SS experience xerostomia, xerophthalmia (dry eyes), fatigue, and pain, which impair quality of life16,59. In a Saudi cohort, 43.9% had a positive fatigue score on the Fatigue Severity Scale (FSS)60. In addition, systemic manifestations occur in approximately 30–40% of patients with SS and include constitutional symptoms (fever, involuntary weight loss, night sweats) as well as renal, pulmonary, nervous, muscular, lymph node, and glandular involvement61. In Saudi Arabia, a study reported 49 patients with primary SS in the Western region between 2015 and 2022. Ocular, oral, and neurological manifestations were observed in 95.9%, 75.5%, and 65.3% of patients, respectively62. A cross-sectional study conducted between 2000 and 2020 in the Southern region of Saudi Arabia reported 29 patients with SS, of whom 34.5% had RA and thyroid disease63. Another cross-sectional, single-center study conducted in the Central region of Saudi Arabia identified 41 patients with primary SS between 2018 and 2019, with pulmonary and articular manifestations reported most frequently64. Notably, the number of patients with SS in these Saudi studies was relatively small despite the long study periods. In contrast, we identified 453 primary SS patients in a multicenter hospital-based study across the Eastern, Western, and Central regions of Saudi Arabia over six years58.
The discrepancy in the reported frequency across these studies may be attributable to several factors. First, accurately estimating SS prevalence is challenging due to changes in diagnostic criteria. Second, methodological heterogeneity may stem from clinician expertise63. Third, delayed diagnosis may result from nonspecific clinical manifestations, the absence of sicca symptoms, and the low sensitivity of autoantibodies65.
Treatment of the systemic manifestations of SS is guided by clinical presentation and disease activity. Hydroxychloroquine (HCQ), for example, may be considered for selected systemic manifestations of SS, particularly inflammatory musculoskeletal pain, constitutional symptoms such as fatigue, and cutaneous involvement66,67,–68. Methotrexate, administered alone or in combination with HCQ, is recommended for managing musculoskeletal manifestations in patients who are unresponsive to HCQ alone. If these therapies are ineffective, corticosteroids, either alone or in combination with immunosuppressive agents, are recommended. In addition, rituximab (an anti-CD20 B-lymphocyte-depleting agent) may be considered for patients with active systemic SS16,68. Treatment strategies differed between the two Saudi cohort studies: HCQ was the most commonly prescribed medication in one study, whereas rituximab, with or without prednisolone, was used more frequently in the other58,63. Interestingly, a negative correlation was observed between systemic manifestations and cytokine levels among Saudi patients. The authors suggested that this finding may be attributable to HCQ use69. These findings may reflect differences in disease severity and clinical presentation, highlighting the heterogeneity of SS in Saudi Arabia. Various immunomodulators, including cytokines and chemokines, as well as inflammatory cells, have been implicated in the pathogenesis of SS70. However, few studies have investigated their role in Saudi Arabia. These studies suggest that cytokine genes 71 and serum human leukocyte antigen-G may be involved in the pathogenesis of SS among patients in Saudi Arabia (Table S2)72.
Salivary gland tumors
Salivary gland tumors (SGTs) are relatively rare, with a global incidence of 0.4–13.5 cases per 100,000 people73. Benign SG tumors are more common, comprising approximately 80% of all SGTs17, whereas malignant SGTs account for less than 0.5% of all cancers74. The PG is the predominant site of SGTs (70%), followed by the SMG (10%). In contrast, SL and minor SGs account for less than 1% and approximately 20% of SGTs, respectively (Fig. 2). Furthermore, SGTs occur in both males and females, most commonly in adults aged ≥ 40 years75. Findings from a Saudi cohort identified 796 SG tumor (SGT) cases between 2010 and 2022 across four tertiary hospitals in the capital of Saudi Arabia; 66.2% were benign. The PG was the most frequently affected site, whereas involvement of the SMG and SL each accounted for less than 10% of cases. In addition, approximately 44% of patients were in the fourth to fifth decades of life73. A study reported 40 SGT cases over a 6-year period (2016–2021) in the Southern region of Saudi Arabia, of which only 10% of patients had malignant tumors76. Another study reported 571 malignant SGTs from the Saudi Cancer Registry between 2008 and 2017, including data from private, military, and Ministry of Health hospitals across five regions in Saudi Arabia. This study found that the highest frequency of malignant SGTs was in the Central and Western regions (Fig. 4)77. The higher number of malignant SGT cases observed in certain regions may reflect differences in population density, as findings from the Saudi Cancer Registry and hospital-based studies do not necessarily represent the true national incidence.
Distribution of malignant SGTs across the Central (orange), Eastern (yellow), Southern (green), Western (blue), and Northern (gray) regions of Saudi Arabia. The data were obtained from a recent study and do not necessarily reflect the true regional distribution of malignant SGTs77. The map was created using BioRender.com.
The World Health Organization (WHO) classification of SGTs has evolved across multiple editions to reflect advances in pathology and diagnostic methods. The most recent 2022 WHO Classification of Head and Neck Tumours (5th edition) recognizes 39 SG entities, categorized as non-neoplastic epithelial lesions, benign and malignant epithelial tumors, and SG-specific mesenchymal tumors78. Among the histopathological subtypes, pleomorphic adenoma and Warthin tumor are the most common benign types, whereas mucoepidermoid carcinoma and adenoid cystic carcinoma are the most common malignant types, consistent with both international79 and Saudi studies (Supplementary Table S2)73,77.
Surgical resection is the primary treatment for localized malignant SGTs, depending on tumor location, size, and histological subtype80. Postoperative radiotherapy is indicated for patients with high-risk features, including high-grade tumors, positive surgical margins, perineural invasion, lymphovascular invasion, lymph node metastases, and pT3–T4 tumors81.
To date, no standardized chemotherapeutic protocol exists because of clinical heterogeneity, the rarity of SG malignancies, limitations in large-scale clinical trials, and the lack of randomized trials comparing treatment regimens81,82,83,84. Consequently, chemotherapy is primarily used for palliative management of unresectable or advanced disease, largely based on clinical experience85. However, published data on systemic therapies, including chemotherapy, in Saudi patients are limited. While malignant SGT diagnosis has traditionally relied on histological and immunohistochemical assessment without mandatory molecular characterization, expanding molecular profiling may inform prognosis, identify candidates for targeted therapies, and guide treatment selection. Systemic therapies, including targeted therapies and chemotherapy, are generally indicated for recurrent or metastatic disease based on the histological subtype81. Several molecular biomarkers may support diagnosis and guide targeted therapy selection. These include human epidermal growth factor receptor 2 (HER2), androgen receptor (AR), and the neurotrophic tyrosine receptor kinase (NTRK) gene family86. For example, trastuzumab may be used for HER2 overexpression, androgen deprivation therapy for AR overexpression, and NTRK inhibitors for NTRK gene fusions84.
Other risk factors relevant to SG hypofunction
Diabetes mellitus
Diabetes mellitus (DM) is the most common endocrine disorder associated with xerostomia and hyposalivation25,87. Several mechanisms have been suggested to contribute to reduced salivary flow in patients with DM, including alterations in the microcirculation of the SGs, damage to the glandular parenchyma, dehydration, and disturbances in glycemic control18. Reduced salivary secretion in DM has been associated with worsening metabolic control, elevated salivary protein concentrations88 and abnormal salivary amylase levels89. The prevalence of xerostomia among patients with DM has been suggested to be influenced by gender, age, and race90. A recent meta-analysis reported a prevalence of xerostomia of approximately 42% in patients with DM across 16 countries 90. DM is a major public health concern in Saudi Arabia because of its increasing incidence over the past two decades91. Low salivary flow rate and salivary pH were reported among Saudi patients with DM, along with increased xerostomia, particularly in older adults (Supplementary Table S2)92.
Radiation exposure
Approximately 900,000 new cases of head and neck cancer (HNC) are diagnosed each year worldwide93. Treatment of HNC typically involves a multidisciplinary approach, with surgery, radiotherapy, chemotherapy, or combinations of these modalities selected according to tumor type, stage, and location94,95. Healthy SGs are radiosensitive, and the extent of damage depends on the radiation dose and the affected gland, particularly the PG and SMG21. Consequently, patients may experience numerous complications that significantly affect quality of life3,96. These complications include dysphagia, chronic dental caries, oral infections, altered taste, impaired mastication, and difficulties in speech 97,98,99,100,101. Management depends on the residual SG function and includes salivary stimulants102, cholinergic agonists103, saliva substitutes102,104, and preventive oral care105.
An estimated 1,925 HNC cases were reported in the Gulf Cooperation Council in 2020, and this number is projected to increase 2- to 3-fold by 2040106. In addition, thyroid cancer is ranked the third most common malignancy in Saudi Arabia107. A recent study found that 78% of Egyptian patients with HNC experienced xerostomia following radiotherapy108. However, data on radiation-induced xerostomia among Saudi patients with HNC remain limited, highlighting the necessity of determining its prevalence in this population. Such data could inform the development of effective management strategies and improve patients’ quality of life.
Lifestyle factors
Other risk factors for xerostomia and SG disorders include smoking and obesity. According to the WHO, there are 1.3 billion tobacco users, of whom 80% live in low- and middle-income countries109. Cigarette smoking is associated with reduced salivary flow110, particularly unstimulated salivary flow23. E-cigarettes are popular among young people111, and young adults constitute a larger proportion of the Saudi population than adults older than 40 years112. According to the Global Tobacco Survey conducted in Saudi Arabia, 14.6% of the population were tobacco users, including cigarettes, waterpipe, and e-cigarettes113. In addition, approximately 24% of e-cigarette users in Saudi Arabia reported dry mouth, based on a self-reported questionnaire114. A study reported reduced unstimulated salivary flow rate and pH among e-cigarette users in Saudi Arabia115. Another study in Saudi Arabia found no differences in salivary flow rate between smokers and nonsmokers; however, salivary biomarkers, including cortisol and interleukin-1β, were higher in smokers (Table S2)116. These findings underscore the need to raise awareness of the potential adverse oral health effects associated with tobacco smoking and e-cigarette use, particularly among younger individuals.
Similarly, obesity has been implicated in xerostomia and oral conditions117. The association between obesity and xerostomia has been reported to be influenced by DM24 and age118. An elevated BMI has been associated with an increased risk of SG disorders, such as sialolithiasis and parotitis36,54. Although the prevalence of obesity in Saudi Arabia is higher than the global average119, the association between obesity and xerostomia in the Saudi population remains unclear.
Aging
The histological structure of the SG changes with age, as the volume of epithelial secretory tissue decreases and intraglandular fat and connective tissue increase120, leading to a decline in salivary secretion121. SG hypofunction, with or without xerostomia, also appears to be driven by age-related factors such as chronic diseases and polypharmacy122. According to a recent study, the prevalence of chronic diseases increases with age, especially among females in Saudi Arabia, including DM, cardiovascular diseases, and RA112. The prevalence of hypertension (22.6%)123, cardiovascular diseases (1.6%)124, and depressive disorders (12.7%)125 is lower in Saudi Arabia than in other countries126,127. One Saudi cross-sectional study found significantly higher Xerostomia Inventory scores among patients with one or more health conditions, including DM and psychological distress128.
Globally, approximately 19.5% of patients with RA have SS129; however, corresponding data from Saudi Arabia remain unavailable. For example, a large-scale study in the United States found that 32.1% of RA patients had SS. These patients were more likely to be older, female, have comorbidities such as hypertension and cardiovascular disease, and exhibit higher disease activity130. Such data are essential for optimizing treatment strategies, improving prognostic assessment, and preventing serious complications.
Medications used to treat these disorders may increase the risk of hypofunction with or without xerostomia (Table 1)19,131. The risk increases with higher doses, longer duration of use, and a greater number of concurrently used medications132,133,134. A systematic review identified chemical subgroups and substances strongly associated with SG hypofunction alone or with xerostomia in patients with hypertension, cardiovascular diseases, and depression19. However, no Saudi studies have explored the association between medication use and SG hypofunction or xerostomia.
Challenges and future perspectives
Although SG dysfunction is attributed to several etiological factors, existing studies are insufficient to provide a comprehensive understanding of the current status of SG disorders in Saudi Arabia. Limited epidemiological evidence, together with substantial heterogeneity in study methodologies, including case reports, case series, and hospital-based studies, makes it difficult to estimate the overall disease burden and identify associations with other disorders. Furthermore, data on several key factors associated with SG dysfunction remain limited or unavailable.
One of the goals of Saudi Vision 2030 is to improve human health and prevent disease. Hence, extensive national-scale research is required to elucidate the epidemiology of SG disorders and their associations with lifestyle factors and comorbidities, thereby addressing existing knowledge gaps and informing targeted prevention and management strategies. Further studies evaluating knowledge of SG disorders among the Saudi population are also warranted to improve public awareness and promote early diagnosis. Establishing Saudi registries for SG disorders would enable accurate estimates of disease burden and facilitate the identification of risk factors. Such registries could also promote standardized diagnostic criteria and salivary flow assessment protocols, integrate dental and medical records, and enable longitudinal monitoring of patient outcomes. This initiative aligns with the objectives of Saudi Arabia’s Health Sector Transformation Program under Vision 2030, which emphasizes disease prevention, early diagnosis, digital health integration, and evidence-based healthcare136. Further investigation of the oral microbiota and metabolites also represents a promising avenue for advancing our understanding of SG disorders in Saudi Arabia. Previous studies have highlighted associations between the oral microbiota and systemic diseases, including obesity137, RA138, and DM139. In addition, saliva is a reservoir for numerous proteins, including cytokines, immunoglobulins, digestive enzymes, and steroids140, as well as more than 800 metabolites141. Characterizing these microbial and molecular profiles may provide valuable insights into disease mechanisms, facilitate the identification of novel biomarkers, and support the development of more effective diagnostic, preventive, and therapeutic strategies.
Conclusion
This review provides a broad overview of the current understanding of SG disorders and their associated factors in Saudi Arabia. It highlights the limited epidemiological evidence, which hinders accurate estimation of disease incidence and burden. The existing literature is characterized by heterogeneous study designs, variable sample sizes, diverse outcome measures, and a predominance of retrospective studies. Therefore, standardized epidemiological and clinical studies are needed to better define the disease burden and inform prevention and management strategies.
Data availability
No datasets were generated or analysed during the current study.
References
Contreras-Aguilar, M. D. & Gómez-García, F. in Saliva in Health and Disease: The Present and Future of a Unique Sample for Diagnosis 3–21 (Springer, 2020).
Ghannam, M. G. & Singh, P. in StatPearls [Internet] (StatPearls Publishing, 2023).
Pedersen, A. M. L., Sørensen, C. E., Proctor, G. B., Carpenter, G. H. & Ekström, J. Salivary secretion in health and disease. J. Oral Rehabil. 45, 730–746. https://doi.org/10.1111/joor.12664 (2018).
Carpenter, G. H. The secretion, components, and properties of saliva. Annu. Rev. Food Sci. Technol.4, 267–276. https://doi.org/10.1146/annurev-food-030212-182700 (2013).
Calado, G., Behl, I., Byrne, H. J. & Lyng, F. M. Raman spectroscopic characterisation of non stimulated and stimulated human whole saliva. Clin. Spectrosc.3, 100010. https://doi.org/10.1016/j.clispe.2021.100010 (2021).
Azevedo, L. R., De Lima, A. A. S., Machado, M. Â. N., Grégio, A. M. T. & de Almeida, P. D. V. Saliva composition and functions: a comprehensive review. J. Contemp. Dent. Pract.9, 72–80 (2009).
Chibly, A. M., Aure, M. H., Patel, V. N. & Hoffman, M. P. Salivary gland function, development, and regeneration. Physiol. Rev.102, 1495–1552. https://doi.org/10.1152/physrev.00015.2021 (2022).
Surdu, A. et al. Saliva as a Diagnostic Tool for Systemic Diseases—A Narrative Review. Medicina61, 243. https://doi.org/10.3390/medicina61020243 (2025).
Brand, H. S., Ligtenberg, A. & Veerman, E. Saliva and wound healing. Monogr. Oral Sci.24, 52r60. https://doi.org/10.1159/000358784 (2014).
Ship, J. Diagnosing, managing, and preventing salivary gland disorders. Oral Dis.8, 77–89. https://doi.org/10.1034/j.1601-0825.2002.2o837.x (2002).
Villa, A., Connell, C. L. & Abati, S. Diagnosis and management of xerostomia and hyposalivation. Ther. Clin. Risk Manag. 45–51. https://doi.org/10.2147/TCRM.S76282 (2014).
Barbe, A. G. Medication-Induced Xerostomia and Hyposalivation in the Elderly: Culprits, Complications, and Management. Drugs Aging. 35, 877–885. https://doi.org/10.1007/s40266-018-0588-5 (2018).
Łysik, D., Niemirowicz-Laskowska, K., Bucki, R., Tokajuk, G. & Mystkowska, J. Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia. Int. J. Mol. Sci.20, 3199. https://doi.org/10.3390/ijms20133199 (2019).
Moore, J., Simpson, M. T. W., Cohen, N., Beyea, J. A. & Phillips, T. Approach to sialadenitis. Can. Fam Physician. 69, 531–536. https://doi.org/10.46747/cfp.6908531 (2023).
Kraaij, S., Karagozoglu, K. H., Forouzanfar, T., Veerman, E. C. & Brand, H. S. Salivary stones: symptoms, aetiology, biochemical composition and treatment. Br. Dent. J.217, E23. https://doi.org/10.1038/sj.bdj.2014.1054 (2014).
Negrini, S. et al. Sjögren’s syndrome: a systemic autoimmune disease. Clin. Exp. Med.22, 9–25. https://doi.org/10.1007/s10238-021-00728-6 (2022).
Mckenzie, J., Lockyer, J., Singh, T. & Nguyen, E. Salivary gland tumours: an epidemiological review of non-neoplastic and neoplastic pathology. Br. J. Oral Maxillofac. Surg.61, 12–18. https://doi.org/10.1016/j.bjoms.2022.11.281 (2023).
Mauri-Obradors, E., Estrugo-Devesa, A., Jané-Salas, E., Viñas, M. & López-López, J. Oral manifestations of Diabetes Mellitus. A systematic review. Med. Oral Patol. Oral Cir. Bucal. 22, e586–e594. https://doi.org/10.4317/medoral.21655 (2017).
Wolff, A. et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 17, 1–28. https://doi.org/10.1007/s40268-016-0153-9 (2017).
Iwasaki, M. et al. Hyposalivation and 10-year all-cause mortality in an elderly Japanese population. Gerodontology35, 87–94. https://doi.org/10.1111/ger.12319 (2018).
Vissink, A. et al. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int. J. Radiat. Oncol. Biol. Phys.78, 983–991. https://doi.org/10.1016/j.ijrobp.2010.06.052 (2010).
Cascarini, L. & McGurk, M. Epidemiology of salivary gland infections. Oral Maxillofacial Surg. Clin.21, 353–357. https://doi.org/10.1016/j.coms.2009.05.004 (2009).
Alaee, A., Azizi, A., Valaie, N. & Moieni, S. The correlation between cigarette smoking and salivary flow rate. J. Res. Dent. Maxillofacial Sci.2, 5–9. https://doi.org/10.29252/jrdms.2.3.5 (2017).
Marquezin, M. C. S. et al. Oral health and nutritional characteristics of adults with morbid obesity: A multivariate analysis. Front. Nutr.7, 589510. https://doi.org/10.3389/fnut.2020.589510 (2020).
Saleh, J., Figueiredo, M. A. Z., Cherubini, K. & Salum, F. G. Salivary hypofunction: an update on aetiology, diagnosis and therapeutics. Arch. Oral Biol.60, 242–255. https://doi.org/10.1016/j.archoralbio.2014.10.004 (2015).
Vissink, A., Burlage, F. R., Spijkervet, F. K., Veerman, E. C. & Nieuw Amerongen, A. V. Prevention and treatment of salivary gland hypofunction related to head and neck radiation therapy and chemotherapy. Support Cancer Ther.1, 111–118. https://doi.org/10.3816/SCT.2004.n.004 (2004).
Vissink, A., Jansma, J., Spijkervet, F. K., Burlage, F. R. & Coppes, R. P. Oral sequelae of head and neck radiotherapy. Crit. Rev. Oral Biol. Med.14, 199–212. https://doi.org/10.1177/154411130301400305 (2003).
Turner, M. D., Hyposalivation & Xerostomia Etiology, Complications, and Medical Management. Dent. Clin. North. Am.60, 435–443. https://doi.org/10.1016/j.cden.2015.11.003 (2016).
Chibly, A. M., Nguyen, T. & Limesand, K. H. Palliative Care for Salivary Gland Dysfunction Highlights the Need for Regenerative Therapies: A Review on Radiation and Salivary Gland Stem Cells. J. Palliat. Care Med.4, 1000180. https://doi.org/10.4172/2165-7386.1000180 (2014).
Adhikari, R. & Soni, A. in StatPearls [Internet] (StatPearls Publishing, 2022).
Patel, P., Scott, S. & Cunningham, S. Challenging Case of Parotitis: A Comprehensive Approach. J. Am. Osteopath. Assoc.117, e137–e140. https://doi.org/10.7556/jaoa.2017.152 (2017).
Brook, I. Acute bacterial suppurative parotitis: microbiology and management. J. Craniofac. Surg.14, 37–40. https://doi.org/10.1097/00001665-200301000-00006 (2003).
Fattahi, T. T., Lyu, P. E. & Van Sickels, J. E. Management of acute suppurative parotitis. J. Oral Maxillofac. Surg.60, 446–448. https://doi.org/10.1053/joms.2002.31234 (2002).
Soriano-Martín, D. et al. Sialendoscopy approach in treating juvenile recurrent parotitis: a systematic review. J. Otolaryngology-Head Neck Surg.52, s40463–s40023. https://doi.org/10.1186/s40463-023-00658-1 (2023).
Wilson, K. F., Meier, J. D. & Ward, P. D. Salivary gland disorders. Am. Fam Physician. 89, 882–888 (2014).
Saleem, R. A. et al. Burden, demographic patterns, and temporal trends of parotitis in Saudi Arabia, 2015–2023: a multicenter electronic health record study. Front. Epidemiol.5, 1742715. https://doi.org/10.3389/fepid.2025.1742715 (2025).
Garavello, W., Redaelli, M., Galluzzi, F. & Pignataro, L. Juvenile recurrent parotitis: A systematic review of treatment studies. Int. J. Pediatr. Otorhinolaryngol.112, 151–157. https://doi.org/10.1016/j.ijporl.2018.07.002 (2018).
Ghabra, Y. A., Goldin, J. & Pandey, S. in StatPearls [Internet] Vol. 2026StatPearls Publishing, (2025).
Reddy, L. M. et al. Upward Trends of Parotitis and Mumps in Atlanta over a Decade. Glob Pediatr. Health. 7, 2333794x20968676. https://doi.org/10.1177/2333794x20968676 (2020).
Albosaily, A. et al. Factors associated with facial weakness following surgery for benign parotid disease: a retrospective multicenter study. Ann. Saudi Med.40, 408–416. https://doi.org/10.5144/0256-4947.2020.408 (2020).
Bukhari, A. F., Bugshan, A. S., Papas, A., Desai, B. & Farag, A. M. Conservative Management of Chronic Suppurative Parotitis in Patients with Sjögren Syndrome: A Case Series. Am. J. Case Rep.22, e929553. https://doi.org/10.12659/ajcr.929553 (2021).
Alkusayer, M. M. et al. Juvenile recurrent parotitis: an eight-year-old boy with a painful acute right-sided parotid swelling. Cureus15, e42632. https://doi.org/10.7759/cureus.42632 (2023).
Al-Ekrish, A. & Al-Sadhan, R. Lipoid proteinosis: A case report with recurrent parotitis and intracranial calcifications. King Saud Univ. J. Dent. Sci.3, 13–19. https://doi.org/10.1016/j.ksujds.2011.10.002 (2012).
Singh, P. P., Goyal, M. & Goyal, A. Sialendoscopic Approach in Management of Juvenile Recurrent Parotitis. Indian J. Otolaryngol. Head Neck Surg.69, 453–458. https://doi.org/10.1007/s12070-017-1223-1 (2017).
Kao, W. K., Chole, R. A. & Ogden, M. A. Evidence of a microbial etiology for sialoliths. Laryngoscope130, 69–74. https://doi.org/10.1002/lary.27860 (2020).
Kraaij, S., Brand, H. S., van der Meij, E. H. & de Visscher, J. G. Biochemical composition of salivary stones in relation to stone- and patient-related factors. Med. Oral Patol. Oral Cir. Bucal. 23, e540–e544. https://doi.org/10.4317/medoral.22533 (2018).
Saleem, R. A. et al. Comorbidity Patterns Among Patients Diagnosed with Sialolithiasis: A Retrospective Analysis. J. Clin. Med.14, 3795. https://doi.org/10.3390/jcm14113795 (2025).
Hiraide, F. & Nomura, Y. The fine surface structure and composition of salivary calculi. Laryngoscope90, 152–158. https://doi.org/10.1288/00005537-198001000-00016 (1980).
Jonas, E. et al. Systemic risk factors contributing to sialolithiasis: A big-data retrospective analysis. Clin. Oral Invest.29, 119. https://doi.org/10.1007/s00784-025-06179-7 (2025).
Schrøder, S. A. et al. Incidence of sialolithiasis in Denmark: a nationwide population-based register study. Eur. Arch. Otorhinolaryngol.274, 1975–1981. https://doi.org/10.1007/s00405-016-4437-z (2017).
Ben Lagha, N., Alantar, A., Samson, J., Chapireau, D. & Maman, L. Lithiasis of minor salivary glands: current data. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100, 345–348. https://doi.org/10.1016/j.tripleo.2004.12.023 (2005).
Pachisia, S., Mandal, G., Sahu, S. & Ghosh, S. Submandibular sialolithiasis: A series of three case reports with review of literature. Clin. Pract.9, 1119. https://doi.org/10.4081/cp.2019.1119 (2019).
Yiu, A., Kalejaiye, A., Amdur, R., Hesham, H. T. & Bandyopadhyay, B. Association of serum electrolytes and smoking with salivary gland stone formation. Int. J. Oral Maxillofac. Surg.45, 764–768. https://doi.org/10.1016/j.ijom.2016.02.007 (2016).
Jonas, E. et al. Characteristics of sialolithiasis in Israel, a big-data retrospective study of 5100 cases. Oral Dis.31, 503–509. https://doi.org/10.1111/odi.15095 (2025).
Ahmed, K. A., Alfadhel, A. K. & Mohammed, B. J. Untreated submandibular megalith for over 60 years. Saudi Med. J.39, 729. https://doi.org/10.15537/smj.2018.7.22265 (2018).
Ali, F. M. et al. Submandibular Duct Salivary Stone Perforating the Floor of the Mouth: Review of Literature and Case Series. J. Int. Dent. Med. Res.16, 1726–1733 (2023).
Mavragani, C. P. & Moutsopoulos, H. M. The geoepidemiology of Sjögren’s syndrome. Autoimmun. Rev.9, A305–310. https://doi.org/10.1016/j.autrev.2009.11.004 (2010).
Saleem, R. A. et al. Laboratory features and pharmacological management of early and late-onset primary Sjögren’s syndrome. Rheumatol. Int.44, 1317–1325. https://doi.org/10.1007/s00296-024-05626-0 (2024).
Meijer, J. M. et al. Health-related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology48, 1077–1082. https://doi.org/10.1093/rheumatology/kep141 (2009).
AlEnzi, F. et al. Fatigue in Saudi Patients with Primary Sjögren’s Syndrome and Its Correlation with Disease Characteristics and Outcome Measures: A Cross-Sectional Study. Open. Access. Rheumatol.12, 303–308. https://doi.org/10.2147/oarrr.S284985 (2020).
Mariette, X. & Criswell, L. A. Primary Sjögren’s syndrome. N. Engl. J. Med.378, 931–939. https://doi.org/10.1056/NEJMcp1702514 (2018).
Elshony, H. et al. Neurological involvement in primary Sjögren’s syndrome: a retrospective analysis of clinical, radiological, laboratory and therapeutic correlations. BMJ Neurol. Open.7, e001227. https://doi.org/10.1136/bmjno-2025-001227 (2025).
Asiri, A., Asiri, M. A. M., Alqhtani, A. M. A. & Asiri, F. M. Exploring the Clinical Spectrum of Sjögren’s Syndrome among Patients at a Tertiary Care Center in Saudi Arabia: A Cross-sectional Registry-based Study. Annals Rheumatol. Autoimmun.5, 41–47. https://doi.org/10.4103/ara.ara_30_24 (2025).
Omair, M. A. et al. Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren’s syndrome: an exploratory cross-sectional study. Saudi Med. J.42, 405. https://doi.org/10.15537/smj.2021.42.4.20200767 (2021).
Martel, C. et al. Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome. J. Clin. Immunol.31, 840–847. https://doi.org/10.1007/s10875-011-9553-3 (2011).
Demarchi, J. et al. Primary Sjögren’s syndrome: extraglandular manifestations and hydroxychloroquine therapy. Clin. Rheumatol.36, 2455–2460. https://doi.org/10.1007/s10067-017-3822-3 (2017).
Vivino, F. B. et al. New Treatment Guidelines for Sjögren’s Disease. Rheum. Dis. Clin. North. Am.42, 531–551. https://doi.org/10.1016/j.rdc.2016.03.010 (2016).
Ramos-Casals, M. et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann. Rheum. Dis.79, 3–18. https://doi.org/10.1136/annrheumdis-2019-216114 (2020).
Alqahtani, B. et al. Association of Inflammatory Cytokine Levels with Extra Glandular Manifestations, Fatigue, and Disease Activity in Primary Sjögren’s Syndrome in Saudi Patients: A Cross-Sectional Study. Diagnostics13, 3036. https://doi.org/10.3390/diagnostics13193036 (2023).
Sisto, M., Ribatti, D. & Lisi, S. Molecular Mechanisms Linking Inflammation to Autoimmunity in Sjögren’s Syndrome: Identification of New Targets. Int. J. Mol. Sci.23, 13229. https://doi.org/10.3390/ijms232113229 (2022).
Alqahtani, B. et al. Single nucleotide polymorphisms in cytokine genes and their association with primary Sjögren’s syndrome in Saudi patients: A cross-sectional study. Saudi Med. J.44, 1232. https://doi.org/10.15537/smj.2023.44.12.20230490 (2023).
Alqarzae, S. A. et al. Heterogeneity of human leukocyte antigen-G (HLA-G) expression in patients with Sjögren’s syndrome. J. King Saud University–Science. 37, 5332025. https://doi.org/10.25259/JKSUS_533_2025 (2025).
AlMaden, N. et al. Relative Frequency of Primary Salivary Gland Tumors: Multicenter Study of 796 Cases from Riyadh, Saudi Arabia. Medicina 60, (2022). https://doi.org/10.3390/medicina60122022 (2024).
Speight, P. & Barrett, A. Salivary gland tumours. Oral Dis.8, 229–240. https://doi.org/10.1034/j.1601-0825.2002.02870.x (2002).
Speight, P. M. & Barrett, A. W. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. Diagn. Histopathology. 26, 147–158. https://doi.org/10.1016/j.mpdhp.2020.01.001 (2020).
Alshehri, M. A. et al. Profile of Salivary Gland Tumor in Aseer Region, Kingdom of Saudi Arabia. Saudi J. Otorhinolaryngol. Head Neck Surg.27, 244–248. https://doi.org/10.4103/sjoh.sjoh_35_24 (2025).
AlSalem, A. et al. Major salivary gland carcinoma in KSA: A 10-year nationwide retrospective study of 571 cases. J. Taibah Univ. Med. Sci.18, 1148–1156. https://doi.org/10.1016/j.jtumed.2023.03.010 (2023).
Żurek, M., Fus, Ł., Niemczyk, K. & Rzepakowska, A. Salivary gland pathologies: evolution in classification and association with unique genetic alterations. Eur. Arch. Otorhinolaryngol.280, 4739–4750. https://doi.org/10.1007/s00405-023-08110-w (2023).
Alsanie, I. et al. Distribution and frequency of salivary gland tumours: an international multicenter study. Head Neck Pathol.16, 1043–1054. https://doi.org/10.1007/s12105-022-01459-0 (2022).
Sreenivasan, S. et al. Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions. Curr. Oncol.32, 232. https://doi.org/10.3390/curroncol32040232 (2025).
Locati, L. D. et al. Current management and future challenges in salivary glands cancer. Front. Oncol.13, 1264287. https://doi.org/10.3389/fonc.2023.1264287 (2023).
Mueller, S. K. et al. Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer. J. Clin. Med.11, 720. https://doi.org/10.3390/jcm11030720 (2022).
Jiménez-Labaig, P. et al. Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges. Crit. Rev. Oncol. Hematol.211, 104747. https://doi.org/10.1016/j.critrevonc.2025.104747 (2025).
Colombo, E. et al. Salivary gland cancers in elderly patients: challenges and therapeutic strategies. Front. Oncol.12–2022https://doi.org/10.3389/fonc.2022.1032471 (2022).
Lagha, A. et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol.4, 19. https://doi.org/10.1186/1758-3284-4-19 (2012).
Nishida, H., Kusaba, T., Kawamura, K., Oyama, Y. & Daa, T. Histopathological Aspects of the Prognostic Factors for Salivary Gland Cancers. Cancers (Basel). 15. https://doi.org/10.3390/cancers15041236 (2023).
López-Pintor, R. M. et al. Xerostomia, Hyposalivation, and Salivary Flow in Diabetes Patients. J. Diabetes Res.2016, 4372852. https://doi.org/10.1155/2016/4372852 (2016).
Aitken-Saavedra, J. et al. Salivary gland dysfunction markers in type 2 diabetes mellitus patients. J. Clin. Exp. Dent.7, e501–505. https://doi.org/10.4317/jced.52329 (2015).
Pérez-Ros, P., Navarro-Flores, E., Julián-Rochina, I., Martínez-Arnau, F. M. & Cauli, O. Changes in Salivary Amylase and Glucose in Diabetes: A Scoping Review. Diagnostics11, 453. https://doi.org/10.3390/diagnostics11030453 (2021).
Huang, S., Zeng, X., Deng, S., He, S. & Liu, F. Prevalence of xerostomia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMC Oral Health. 25, 662. https://doi.org/10.1186/s12903-025-05992-6 (2025).
Alsuliman, M. A., Alotaibi, S. A., Zhang, Q. & Durgampudi, P. K. A systematic review of factors associated with uncontrolled diabetes and meta-analysis of its prevalence in Saudi Arabia since 2006. Diab./Metab. Res. Rev.37, e3395. https://doi.org/10.1002/dmrr.3395 (2021).
Al-Maweri, S. A. et al. Salivary Flow, and Oral Health Status Among Saudi Diabetic Patients: A Comparative Cross-Sectional Study. Clin. Cosmet. Investig Dent.13, 451–458. https://doi.org/10.2147/ccide.S337581 (2021). Xerostomia.
Chow, L. Q. M. Head and Neck Cancer. N Engl. J. Med.382, 60–72. https://doi.org/10.1056/NEJMra1715715 (2020).
Grundmann, O., Mitchell, G. & Limesand, K. Sensitivity of salivary glands to radiation: from animal models to therapies. J. Dent. Res.88, 894–903. https://doi.org/10.1177/0022034509343143 (2009).
Winter, C. et al. Investigation of Changes in Saliva in Radiotherapy-Induced Head Neck Cancer Patients. Int. J. Environ. Res. Public. Health. 18https://doi.org/10.3390/ijerph18041629 (2021).
Dirix, P., Nuyts, S. & Van den Bogaert, W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer: Interdisciplinary Int. J. Am. Cancer Soc.107, 2525–2534. https://doi.org/10.1002/cncr.22302 (2006).
Wang, X. & Eisbruch, A. IMRT for head and neck cancer: reducing xerostomia and dysphagia. J. Radiat. Res.57 (Suppl 1), i69–i75. https://doi.org/10.1093/jrr/rrw047 (2016).
Wu, V. W. C. & Leung, K. Y. A Review on the Assessment of Radiation Induced Salivary Gland Damage After Radiotherapy. Front. Oncol.9, 1090. https://doi.org/10.3389/fonc.2019.01090 (2019).
Hamlet, S. et al. Mastication and swallowing in patients with postirradiation xerostomia. Int. J. Radiation Oncology* Biology* Phys.37, 789–796. https://doi.org/10.1016/s0360-3016(96)00604-9 (1997).
Onjukka, E. et al. Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study. Front. Oncol.10, 1647. https://doi.org/10.3389/fonc.2020.01647 (2020).
Roh, J. L., Kim, A. Y. & Cho, M. J. Xerostomia following radiotherapy of the head and neck affects vocal function. J. Clin. Oncol.23, 3016–3023. https://doi.org/10.1200/JCO.2005.07.419 (2005).
Nieuw Amerongen, A. V. & Veerman, E. C. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer. 11, 226–231. https://doi.org/10.1007/s00520-002-0409-5 (2003).
Berk, L. B., Shivnani, A. T. & Small, W. Jr. Pathophysiology and management of radiation-induced xerostomia. J. Support Oncol.3, 191–200 (2005).
Porter, S. R., Scully, C. & Hegarty, A. M. An update of the etiology and management of xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 97, 28–46. https://doi.org/10.1016/j.tripleo.2003.07.010 (2004).
Hong, C. et al. MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients. Support. Care Cancer. 32, 548. https://doi.org/10.1007/s00520-024-08688-9 (2024).
Alsharif, A. et al. Forecasting head and neck cancer trends in GCC countries: implications for public health policy and strategy. Risk Manage. Healthc. Policy. 2943–2952. https://doi.org/10.2147/RMHP.S445162 (2023).
International Agency for Research on Cancer. Saudi Arabia Fact Sheet 2022, < (2022). https://gco.iarc.who.int/media/globocan/factsheets/populations/682-saudi-arabia-fact-sheet.pdf Accessed 24 May 2026.
Abou-Bakr, A., Hassanein, F. E., William, H. & Ibrahim, S. S. Prevalence of late xerostomia and hyposalivation with associated risk factors in survivors of head and neck cancer after radiotherapy: a multi-centric cross-sectional study. Radiat. Oncol.20, 1–15. https://doi.org/10.1186/s13014-025-02737-1 (2025).
World Health Organization. Tobacco, (2025). https://www.who.int/news-room/fact-sheets/detail/tobacco Accessed 29 May 2026.
Rad, M., Kakoie, S., Niliye Brojeni, F. & Pourdamghan, N. Effect of Long-term Smoking on Whole-mouth Salivary Flow Rate and Oral Health. J. Dent. Res. Dent. Clin. Dent. Prospects. 4, 110–114. https://doi.org/10.5681/joddd.2010.028 (2010).
Rom, O., Pecorelli, A., Valacchi, G. & Reznick, A. Z. Are E-cigarettes a safe and good alternative to cigarette smoking? Ann. N Y Acad. Sci.1340, 65–74. https://doi.org/10.1111/nyas.12609 (2015).
Salam, A. A. Ageing in Saudi Arabia: new dimensions and intervention strategies. Sci. Rep.13, 4035. https://doi.org/10.1038/s41598-022-25639-8 (2023).
Monshi, S. S. et al. Factors associated with the desire to quit tobacco smoking in Saudi Arabia: Evidence from the 2019 Global Adult Tobacco Survey. Tob. Induc. Dis.21, 33. https://doi.org/10.18332/tid/159735 (2023).
Habib, E. et al. Prevalence and perceptions of e-cigarette use among medical students in a Saudi University. J. Family Med. Prim. Care. 9, 3070–3075. https://doi.org/10.4103/jfmpc.jfmpc_235_20 (2020).
Alsenani, M. et al. Correlation between e-cigarette use and salivary flow rate, pH, and buffering capacity: a cross-sectional pilot study. BMC Oral Health. 25, 1806. https://doi.org/10.1186/s12903-025-07255-w (2025).
Alhumaidan, A. A., Al-Aali, K. A., Vohra, F., Javed, F. & Abduljabbar, T. Comparison of Whole Salivary Cortisol and Interleukin 1-Beta Levels in Light Cigarette-Smokers and Users of Electronic Nicotine Delivery Systems before and after Non-Surgical Periodontal Therapy. Int. J. Environ. Res. Public Health. 19, 11290. https://doi.org/10.3390/ijerph191811290 (2022).
Pérez-González, A. et al. Association between xerostomia, oral and general health, and obesity in adults. A cross-sectional pilot study. Med. Oral Patol. Oral Cir. Bucal. 26, e762–e769. https://doi.org/10.4317/medoral.24731 (2021).
Khongsirisombat, N., Kiattavorncharoen, S. & Thanakun, S. Increased Oral Dryness and Negative Oral Health-Related Quality of Life in Older People with Overweight or Obesity. Dentistry J.10, 231. https://doi.org/10.3390/dj10120231 (2022).
DeNicola, E., Aburizaiza, O. S., Siddique, A., Khwaja, H. & Carpenter, D. O. Obesity and public health in the Kingdom of Saudi Arabia. Rev. Environ. Health. 30, 191–205. https://doi.org/10.1515/reveh-2015-0008 (2015).
Scott, J. Quantitative age changes in the histological structure of human submandibular salivary glands. Arch. Oral Biol.22, 221–227. https://doi.org/10.1016/0003-9969(77)90158-3 (1977).
Affoo, R. H., Foley, N., Garrick, R., Siqueira, W. L. & Martin, R. E. Meta-analysis of salivary flow rates in young and older adults. J. Am. Geriatr. Soc.63, 2142–2151. https://doi.org/10.1111/jgs.13652 (2015).
Fornari, C. B., Bergonci, D., Stein, C. B., Agostini, B. A. & Rigo, L. Prevalence of xerostomia and its association with systemic diseases and medications in the elderly: a cross-sectional study. Sao Paulo Med. J.139, 380–387. https://doi.org/10.1590/1516-3180.2020.0616 (2021).
Alshammari, S. A., Alshammari, A. S., Alshammari, H. S. & Ahamed, S. S. Overview of hypertension in Saudi Arabia. A systematic review and meta-analysis 44, 951–964. (2023). https://doi.org/10.15537/smj.2023.44.10.20230178
Alqahtani, B. A. & Alenazi, A. M. A national perspective on cardiovascular diseases in Saudi Arabia. BMC Cardiovasc. Disord.24, 184. https://doi.org/10.1186/s12872-024-03845-8 (2024).
Alhabeeb, A. A. et al. National screening for anxiety and depression in Saudi Arabia 2022. Front. public. health. 11, 1213851. https://doi.org/10.3389/fpubh.2023.1213851 (2023).
Mohammadian Khonsari, N. et al. Long-term Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rate in the Middle East and North Africa: a Systematic Review and Meta-analysis of 178 Population-Based Studies. Curr. Hypertens. Rep.23, 41. https://doi.org/10.1007/s11906-021-01159-0 (2021).
Gałecki, P., Samochowiec, J., Mikułowska, M. & Szulc, A. Treatment-Resistant Depression in Poland—Epidemiology and Treatment. J. Clin. Med.11, 480. https://doi.org/10.3390/jcm11030480 (2022).
Mumtaz, M. et al. Prevalence of xerostomia and associated systemic risk factors in Riyadh, Saudi Arabia: a cross-sectional study. J. Pharm. Res. Int.33, 186–194. https://doi.org/10.9734/jpri/2021/v33i56B33944 (2021).
Alani, H., Henty, J. R., Thompson, N. L., Jury, E. & Ciurtin, C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand. J. Rheumatol.47, 141–154. https://doi.org/10.1080/03009742.2017.1324909 (2018).
Harrold, L. R. et al. Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. Clin. Rheumatol.39, 1899–1905. https://doi.org/10.1007/s10067-020-05004-8 (2020).
Tan, E. C., Lexomboon, D., Sandborgh-Englund, G., Haasum, Y. & Johnell, K. Medications that cause dry mouth as an adverse effect in older people: a systematic review and metaanalysis. J. Am. Geriatr. Soc.66, 76–84. https://doi.org/10.1111/jgs.15151 (2018).
Guggenheimer, J. & Moore, P. A. Xerostomia: etiology, recognition and treatment. J. Am. Dent. association. 134, 61–69. https://doi.org/10.14219/jada.archive.2003.0018 (2003).
Närhi, T. O. et al. Association between salivary flow rate and the use of systemic medication among 76-, 81-, and 86-year-old inhabitants in Helsinki, Finland. J. Dent. Res.71, 1875–1880. https://doi.org/10.1177/00220345920710120401 (1992).
Wu, A. J. & Ship, J. A. A characterization of major salivary gland flow rates in the presence of medications and systemic diseases. Oral Surg. Oral Med. Oral Pathol.76, 301–306. https://doi.org/10.1016/0030-4220(93)90258-6 (1993).
Smidt, D., Torpet, L. A., Nauntofte, B., Heegaard, K. M. & Pedersen, A. M. L. Associations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. Commun. Dent. Oral Epidemiol.38, 422–435. https://doi.org/10.1111/j.1600-0528.2010.00554.x (2010).
Vision Health Sector Transformation Program, (2030). https://www.vision2030.gov.sa/en/explore/programs/health-sector-transformation-program (2026). Accessed 29 May 2026.
Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature488, 178–184. https://doi.org/10.1038/nature11319 (2012).
Scher, J. U. et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum.64, 3083–3094. https://doi.org/10.1002/art.34539 (2012).
Long, J. et al. Association of oral microbiome with type 2 diabetes risk. J. Periodontal Res.52, 636–643. https://doi.org/10.1111/jre.12432 (2017).
Garcia, P. N. et al. Saliva metabolomics: concepts and applications in oral disorders. Clin. Oral Investig. 28, 579. https://doi.org/10.1007/s00784-024-05990-y (2024).
Dame, Z. T. et al. The human saliva metabolome. Metabolomics11, 1864–1883. https://doi.org/10.1007/s11306-015-0840-5 (2015).
Funding
No financial support was received for this review article.
Author information
Authors and Affiliations
Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia
Rimah Abdullah Saleem
Authors
- Rimah Abdullah Saleem
Contributions
R.A.S. conceived the review topic, conducted the literature search, screened and analyzed the relevant information, prepared the tables and figures, wrote, reviewed, and approved the final version of the manuscript.
Author biographies
Rimah Abdullah Saleem, PhD, is an Assistant Professor of Biochemistry and Molecular Medicine at Alfaisal University in Riyadh, Saudi Arabia. Her research focuses on salivary gland disorders and regenerative medicine. Her academic profile is available at https://orcid.org/0000-0002-4654-245X and https://scholar.google.com/citations?user=jmBrIocAAAAJ&hl=ar&oi=ao.
Corresponding author
Correspondence to Rimah Abdullah Saleem.
Ethics declarations
Ethics approval and consent to participate
Not applicable; this review is based exclusively on previously published literature and did not involve participants, human data, animal subjects, or biological materials that require ethical approval.
Consent for publication
Not applicable.
Professional relationship between authors
Not applicable. This manuscript was prepared by a single author.
Lead author
R.A.S.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Saleem, R.A. Current understanding of salivary gland disorders and related factors in Saudi Arabia: epidemiology, risk factors, clinical features, and future perspectives. Sci. Rev. 1, 27 (2026). https://doi.org/10.1038/s44573-026-00026-w
Received: 12 June 2026
Revised: 18 September 2026
Accepted: 29 September 2026
Published: 09 November 2026
Version of record: 09 November 2026
DOI: https://doi.org/10.1038/s44573-026-00026-w
Keywords
来源:Nature 健康护理主题 · nature.com